Commercial analytics for cell and gene therapy (CGT) uses patient, physician, treatment-center, claims, and access data to show how many patients can realistically be identified, referred, and treated after launch. It matters because an approved CGT can still struggle commercially when the healthcare system is not ready to deliver it, even when the science and the demand are there.

For example, once a physician identifies a patient as a potential candidate for a CGT, the patient may have to undergo additional testing, get referred to a treatment center that can treat the patient, obtain financial authorization, and go through multiple assessments before starting treatment. Some therapies also require patient-specific manufacturing and are logistics intensive.

Multiplied across many hospitals, physicians, and geographic markets, this becomes a commercial planning problem, because only a limited network of qualified centers can deliver the therapy.

For CGT manufacturers, it’s not enough to know the size of the market. Manufacturers also need to know where their patients are, which treatment centers will be able to treat those patients, and where the patients may be getting stuck.

Commercial analytics is especially useful here, because it can be used to combine the data on treatment centers with healthcare provider data, claims, and insights on the patient journey, so that companies can make informed decisions about their launch planning, resources, and demand forecast.

1. What Is Commercial Analytics for Cell and Gene Therapy?

 

Commercial analytics is using healthcare data and market data to support decision making throughout the commercialization lifecycle of a cell and gene therapy.

But there’s a difference between the number of patients eligible to receive a therapy, and the number of patients who are likely to receive the therapy.

For example, a company may find that there are a large number of patients with a condition, based on their research into the epidemiology of the disease. However, if they only have a few centers that can deliver the therapy, then the commercially addressable market may be very different.

That is why CGT analytics need to bring several dimensions together:

  • Patient population and clinical eligibility.
  • Treatment-center availability and readiness.
  • Physician networks and referral activity.
  • Patient access and reimbursement.
  • Treatment capacity and delivery timelines.

Traditional pharmaceutical analytics often rely heavily on prescription trends, HCP segmentation, and market share. But CGT commercialization requires a broader view.

The approach also depends on the therapy. An autologous cell therapy may involve collecting a patient’s cells, sending them for manufacturing, and coordinating their return for infusion. An in vivo gene therapy follows a different delivery model. Treating both with the same commercial forecasting assumptions would be a mistake.

Delivery models also change who must be ready, and when. Autologous therapies depend on cell collection, manufacturing slots, and scheduled infusion, while allogeneic and in vivo products shift the constraints toward product supply and site capability. Treatment-center capacity and the timing of each step should be modeled separately for each therapy.

2. Why Is Treatment-Center Data Important for CGT Launches?

 

Treatment centers aren’t just another account segment in a commercial database. For many advanced therapies, they’re a critical part of the delivery infrastructure.

A hospital may have a strong oncology department or a large patient population, but that doesn’t automatically make it suitable for administering a specific cell or gene therapy.

Manufacturers need to evaluate clinical capabilities, staffing, infrastructure, patient access, and operational readiness.

For example, a CAR T-cell treatment program may require apheresis facilities, trained clinical teams, appropriate product-handling arrangements, and the ability to manage complications such as cytokine release syndrome.

A useful treatment-center assessment should consider three things.

Clinical capabilities: Does the facility have the required infrastructure, qualified personnel, and relevant treatment experience?

Patient opportunity: Does the center serve a meaningful population of potentially eligible patients? What referral relationships does it have with surrounding hospitals and specialists?

Operational readiness: Has the center completed the necessary onboarding, training, qualification, and product-specific activation requirements?

The last point often gets overlooked. A facility might look promising on paper but still be months away from treating its first commercial patient.

In Deloitte’s 2024 advanced therapy industry survey, treatment center capacity and constraints ranked as the second most significant barrier to patient access, after reimbursement challenges.

Readiness also depends on the manufacturer. ZS recommends assessing launch readiness during clinical development, mapping the full patient and product journey, and testing it with internal and external dry runs, because workflows that work in a trial often fail at commercial scale. ZS also notes that treatment centers need new levels of support, workflows, and scheduling systems when they move from clinical trials to commercial delivery.

How Should Companies Prioritize Treatment Centers?

Not every facility deserves the same level of commercial attention. A simple segmentation model can help teams decide where to concentrate their resources.

Treatment-center category

Characteristics

Commercial priority

High potential, ready

Strong patient opportunity and operational readiness

Immediate engagement

High potential, not ready

Good market opportunity but incomplete activation

Support onboarding

Moderate potential, ready

Operationally capable, limited patient activity

Build referral networks

Emerging potential

Developing capabilities or limited current demand

Monitor for future expansion

This approach gives commercial leaders something more useful than a list of hospitals ranked by size or location.

3. How Can Patient Journey Analytics Improve CGT Commercialization?

 

Here’s a question worth asking: if a company knows that potential patients exist in a market, why aren’t more of them receiving treatment?

The answer may sit somewhere between diagnosis and treatment administration.

Patient journey analytics helps companies examine these gaps. It tracks how patients move through the healthcare system, from initial identification and referral to eligibility assessment, authorization, and treatment.

For an autologous cell therapy, the journey may involve:

Patient identification and referral: A physician identifies a potential candidate and refers the patient to an appropriate specialist or treatment center.

Eligibility assessment: Clinical teams evaluate whether the patient meets the therapy’s specific requirements.

Authorization and access: The required payer approvals and administrative processes are completed.

Collection and manufacturing: Where applicable, the patient’s cells are collected and sent for processing.

Treatment administration: The product is delivered once the patient and therapy are ready.

Post-treatment follow-up: Patients receive the monitoring and follow-up care required for the particular therapy.

Each stage creates an opportunity to understand where delays occur.

What Should Commercial Teams Measure?

Patient journey stage

Useful metric

What it reveals

Identification

Potential patients identified

Market opportunity

Referral

Referral volume

Physician network effectiveness

Evaluation

Completed assessments

Patient progression

Eligibility

Eligible patients

Addressable population

Authorization

Approval rate

Access barriers

Scheduling

Confirmed treatment dates

Operational delays

Administration

Completed treatments

Actual treatment volume

Consider a hypothetical launch with 100 potentially eligible patients. Sixty reach a treatment center, 40 complete their evaluations, and 18 eventually receive therapy.

Looking only at the final number tells us very little. Where did the other patients go?

Some may not have met clinical eligibility criteria. Others may have faced reimbursement challenges or dropped out during the referral process. A few may have encountered treatment scheduling delays.

Patient journey analytics helps separate these issues instead of treating every lost patient as a missed commercial opportunity.

Access barriers deserve their own tracking. In Deloitte’s 2024 survey, reimbursement challenges were the most cited barrier to patient access, and more than 80% of respondents saw value-based outcomes and annuity models as the payment models most likely to be adopted for high-cost therapies. Authorization rates and payment-model terms should therefore sit alongside referral and capacity data.

4. How Does Commercial Analytics Support Forecasting in Small-Volume Markets?

 

Forecasting gets tricky when a therapy targets a relatively small patient population.

A conventional pharmaceutical forecast might use historical prescriptions, market growth, physician adoption, and competitor activity. Those inputs can be useful for CGT products too, but they don’t tell the whole story.

There may be very little historical sales data to work with. Patients could be concentrated in a few regions. Treatment eligibility may depend on specific clinical or genetic criteria. And even when demand exists, treatment centers and manufacturing capacity can limit how many patients receive therapy.

A bottom-up forecast offers a more practical starting point.

What Data Is Needed for CGT Demand Forecasting?

Data source

What it helps establish

Epidemiological data

Disease incidence and prevalence

Clinical data

Treatment eligibility

HCP data

Specialists and referral networks

Claims data

Diagnosis and treatment patterns

Treatment-center data

Site readiness and capacity

Patient journey data

Referral and treatment conversion

Market access data

Reimbursement and authorization trends

Building a Practical Forecast

The process starts with the total patient population, but it shouldn’t end there.

Companies need to narrow the estimate based on clinical eligibility, identify how many potential patients can realistically be reached, understand referral rates, and account for treatment-center capacity.

A simplified model looks like this:

Expected treatments = Eligible population × Identification rate × Referral rate × Treatment conversion rate

For example, assume a hypothetical market has 1,000 patients, of whom 40% meet the therapy’s clinical eligibility criteria. If 70% can be identified, 60% are referred, and 75% ultimately receive treatment, the estimated volume is 126 treatments.

That’s a planning illustration, not an industry benchmark.

The assumptions should also be tested against different scenarios. What happens if a treatment center takes three additional months to become operational? What if referral volumes are lower than expected? What if manufacturing turnaround affects scheduling?

Those are the questions a useful commercial forecast should answer.

Manufacturing and scheduling capacity belong in the model as well. In Deloitte’s survey, more than 40% of respondents lacked confidence that they could meet demand over the next two to three years, and ZS describes scheduling bottlenecks at treatment centers that grow as more patients are treated.

5. What Data Sources Are Used in CGT Commercial Analytics?

 

One dataset rarely tells the complete story. Treatment-center records may reveal facility capabilities, but they won’t necessarily show how many eligible patients are being referred. Claims can reveal healthcare utilization, but they may not capture every step of a patient’s treatment journey.

Companies need to connect the dots.

Data source

Information captured

Commercial application

Treatment-center data

Location, capabilities, readiness

Site prioritization

HCP data

Specialties, affiliations, locations

Physician segmentation

Claims data

Diagnoses, procedures, utilization

Market assessment

Epidemiological data

Incidence and prevalence

Patient population estimation

Patient journey data

Referral and treatment milestones

Funnel analysis

Clinical trial data

Trial locations and investigators

Research and geographic intelligence

The real analytical work begins when these datasets are brought together.

For instance, a company might identify a concentration of potential patients in a particular region through epidemiological data. HCP information could reveal the specialists treating those patients, while treatment-center records would show whether suitable facilities are available nearby.

Claims and referral information can add another layer, helping teams understand actual healthcare activity rather than relying entirely on population estimates.

Of course, integration comes with its own challenges. Duplicate provider records, inconsistent hospital identifiers, missing data, and different reporting formats can affect the quality of the analysis. Patient-level data also requires appropriate privacy controls and lawful access.

6. What Are the Key Commercial Analytics Use Cases for CGT Companies?

 

Once the data is integrated, commercial analytics can support several decisions.

Treatment-center prioritization: Identify facilities with the strongest combination of patient opportunity and operational readiness.

Referral network analysis: Understand how patients move between referring physicians, hospitals, and specialized treatment centers.

Patient funnel optimization: Find the stages where patients are dropping out and investigate the underlying reasons.

Territory planning: Allocate field resources based on treatment-center networks, HCP relationships, and geographic opportunity.

Demand and capacity forecasting: Compare expected patient volumes with treatment-center and manufacturing capacity.

Launch performance monitoring: Track site activation, referral activity, treatment volumes, and geographic market penetration.

The common thread is simple: commercial teams need to understand not just where demand exists, but whether the system can convert that demand into treatment.

7. How Can Companies Build a CGT Commercial Analytics Framework?

 

A useful framework doesn’t need to start with an elaborate technology implementation. It needs to start with the right business questions.

First, define what the commercial team wants to understand. Is the priority treatment-center selection, patient identification, referral optimization, or demand forecasting?

Next, identify the datasets required to answer those questions. This could include HCP records, claims, epidemiological information, treatment-center databases, and patient journey information.

The next step is data integration. Standardize provider and facility records, resolve duplicates, map HCPs to their affiliated organizations, and normalize geographic information. Where patient-level linkage is permitted, establish appropriate privacy and governance controls.

With the data in place, analytical models can support center segmentation, referral network mapping, patient funnel analysis, and demand forecasting.

Predictive models can add a further layer, for example by ranking centers by likelihood of early activation or flagging patients at risk of delay. With small patient volumes, these models have limited training data, so their outputs should support planning decisions and be checked against observed launch data.

Finally, make the results accessible. Commercial leaders need dashboards that explain what’s happening across their markets, not another spreadsheet full of disconnected metrics.

The framework should also evolve after launch. New patient activity, site activation, and treatment volumes will gradually replace some of the assumptions made during pre-launch planning.

8. What KPIs Should Companies Track During a CGT Launch?

 

Revenue matters, naturally. But it doesn’t explain everything happening during a CGT launch.

Commercial teams should also monitor the operational indicators that influence treatment delivery.

KPI

What it measures

Treatment-center activation rate

Activated sites against targeted sites

Site readiness rate

Facilities meeting operational requirements

Patient identification rate

Identified patients against estimated opportunity

Referral conversion rate

Patients referred against identified patients

Eligibility conversion rate

Patients qualifying after assessment

Authorization rate

Approved requests against submissions

Time to treatment

Time between defined patient journey milestones

Treatment throughput

Treatments administered over a period

Capacity utilization

Used capacity against available capacity

Forecast accuracy

Forecast versus actual treatment volume

These metrics are more useful when viewed together.

For example, a company may have activated most of its targeted treatment centers but still see limited treatment volumes. The immediate reaction might be to expand commercial engagement. But perhaps the problem lies earlier in the patient journey, with weak referral networks or limited patient identification.

Without the right data, it’s easy to solve the wrong problem.

Conclusion

 

Cell and gene therapy launches demand more than a conventional commercial analytics model. The patient population may be small, treatment delivery is specialized, and several operational dependencies influence whether demand translates into actual treatment.

Companies need a connected view of patients, physicians, treatment centers, and market access. That’s what makes treatment-center intelligence, patient journey analytics, and small-volume forecasting so valuable.

The objective isn’t to collect more data for the sake of it. It’s to understand where commercial opportunities exist, where patients encounter barriers, and where resources can make the greatest difference.

For CGT manufacturers, better commercial decisions begin with seeing the entire treatment ecosystem, not just the market opportunity.

Frequently Asked Questions

What is commercial analytics in cell and gene therapy?

Commercial analytics for cell and gene therapy (CGT) combines patient, physician, treatment-center, claims, and access data to show how many eligible patients can realistically be identified, referred, and treated after launch. It goes beyond market size to show where patients are, which centers can treat them, and where they drop out of the journey.

Traditional pharmaceutical analytics centers on prescription trends, HCP (healthcare professional) segmentation, and market share. CGT analytics adds treatment-center readiness, referral networks, patient-journey timing, manufacturing and scheduling capacity, and payer authorization, because delivery depends on a small network of qualified centers rather than on prescribers alone.

Treatment centers are part of the delivery system for most advanced therapies, so a launch can stall when centers are not ready even if demand exists. In Deloitte’s 2024 advanced therapy survey, treatment center capacity and constraints ranked as the second most significant barrier to patient access, after reimbursement challenges.

Manufacturers should track clinical capabilities (such as apheresis and cell-handling infrastructure and trained staff), onboarding and activation status, referral relationships, patient volumes, and scheduling capacity. Combined with HCP and claims data, this shows which centers are both able and likely to treat patients early.

Teams usually start with epidemiology and clinical eligibility criteria, then use claims, HCP, and treatment-center data to estimate where those patients are seen and which physicians refer them. Patient-level estimates should be treated as ranges, since small populations make precise counts hard.

The main barriers are delayed referral, eligibility assessment, payer authorization, treatment-center capacity, and manufacturing or scheduling slots. In Deloitte’s 2024 survey, reimbursement challenges were the most cited barrier to patient access.

Patient journey analytics tracks how patients move from identification to treatment and measures where they stall, such as referral-to-evaluation time or authorization delays. Separating clinical drop-offs from access or operational drop-offs lets teams fix the right problem instead of treating every lost patient as a missed opportunity.

A bottom-up forecast is usually more practical than a prescription-based one. It starts with the eligible population and applies identification, referral, and treatment conversion rates, then tests scenarios such as late center activation. A simplified form is: expected treatments = eligible population × identification rate × referral rate × treatment conversion rate.


Submit a Comment

Your email address will not be published. Required fields are marked *